drugset
drugset / Trial / NCT05487742

Neuroprotective Effect of Dexomitomidine

NCT05487742 ↗

Phase 1 Unknown 80 enrolled Tanta University
RandomizedParallel-groupTriple-blindPrevention

Summary

patient wih mild to moderate traumatic brain injury in ICU will be randomisly distributed into two groups Group I (control group): Patients of this group receive placebo infusion for 72 hours. Group II (DEX group): Patients of this group receive 0.5 ug/kg/hr dexmedetomidine continuous infusion for 72 hour Patient demographics, including age, sex, weight, primary diagnosis, Acute Physiology and Chronic Health Evaluation (APACHE) II score and postresuscitation Glasgow Coma Scale (GCS) score will be collected. CBF will be measured at pre-sedation and after cessation of sedation (dexmedetomidine administration). The CMRe and CMRe/CBF will also be calculated. Measurements of blood gas analysis and haemodynamic parameters \[systolic blood pressure (SBP), diastolic blood pressure (DBP), MAP and heart rate (HR)\] will be collected at pre-sedation and after cessation of sedation (dexmedetomidine administration).

Timeline

Start
2022-06-04
Primary completion
2022-12
Completion
2023-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous

Indications

No indication recorded.